Contineum Therapeutics, Inc. Class A Common Stock
General ticker "CTNM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $359.7M (TTM average)
Contineum Therapeutics, Inc. Class A Common Stock follows the US Stock Market performance with the rate: 43.6%.
Estimated limits based on current volatility of 4.4%: low 11.95$, high 13.06$
Factors to consider:
- Total employees count: 51 (+24.4%) as of 2025
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.72$, 19.01$]
- 2026-12-31 to 2027-12-31 estimated range: [5.46$, 14.23$]
Short-term CTNM quotes
Long-term CTNM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $50.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $33.92MM | $50.89MM | $68.06MM |
| Operating Income | $16.08MM | $-50.89MM | $-68.06MM |
| Non-Operating Income | $7.09MM | $8.64MM | $8.08MM |
| Interest Expense | $0.21MM | $0.00MM | $0.00MM |
| R&D Expense | $27.60MM | $38.42MM | $51.52MM |
| Income(Loss) | $23.17MM | $-42.26MM | $-59.98MM |
| Taxes | $0.45MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $22.72MM | $-42.26MM | $-59.98MM |
| Stockholders Equity | $-67.94MM | $198.07MM | $260.99MM |
| Assets | $130.39MM | $212.85MM | $276.64MM |
| Operating Cash Flow | $19.35MM | $-32.84MM | $-55.31MM |
| Capital expenditure | $0.41MM | $0.51MM | $0.23MM |
| Investing Cash Flow | $-65.57MM | $-69.74MM | $-3.71MM |
| Financing Cash Flow | $56.18MM | $109.00MM | $112.69MM |
| Earnings Per Share** | $0.90 | $-1.63 | $-2.17 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.